Lung Cancer
A PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF TIRAGOLUMAB, AN ANTI-TIGIT ANTIBODY,IN COMBINATION WITH ATEZOLIZUMAB COMPARED WITH PLACEBO IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PD-L1-SELECTED NON-SMALL CELL LUNG CANCER (GO41717)
- Details
ClinicalTrials.gov ID:
NCT04294810
Diagnosis Type:
NSCLC
USOR Number:
- Address
310 Smith Ave N
Suite 100
Saint Paul, MN 55102
P: (651) 251-5500